Characterization of adaptive immune response to vaccination or infection using immune repertoire sequencing
Methods of monitoring and measuring dynamic adaptive immune cell responses are provided. High-throughput sequencing of T cell receptor and immunoglobulin loci is used to characterize the breadth of an effector cell response to a stimulus, such as a vaccine or infection. Unique responding effector cell clones and abundance thereof can be determined. Additionally, methods for determining the contribution of responding effector cells to the immunological memory compartment are provided.
1. A method of measuring T cell response to a vaccine in a subject, comprising:
performing high-throughput sequencing of nucleic acid molecules comprising rearranged CDR3 regions of TCR loci obtained from a first biological sample of the subject at a first time point post vaccination, wherein the first biological sample is obtained at least 10 days post vaccination;
sorting activated T cells from a subset of the first biological sample using flow cytometry to generate a set of activated T cells;
performing high-throughput sequencing of nucleic acid molecules comprising rearranged CDR3 regions of TCR loci obtained from the set of activated T cells; and
identifying activated T cell clones in the set having CDR3 regions of significantly higher proportional abundance in the activated T cell population in comparison to the first biological sample, thereby identifying vaccine-induced responsive clones.
2. The method of claim 1 , wherein the TCR loci are selected from the group consisting of the TCRα locus, TCRβ locus, TCRγ locus, and TCRδ locus.
3. The method of claim 1 , wherein the biological samples comprise peripheral blood mononuclear cells (PBMCs).
4. The method of claim 1 , wherein the biological samples comprise memory T cells.
5. The method of claim 1 , further comprising performing multiplex PCR amplification of genomic templates comprising rearranged CDR3 regions to produce nucleic acid molecules for sequencing.
6. The method of claim 1 , wherein identifying comprises calculating a false discovery rate, and wherein the calculating comprises performing a computation on a computer.
7. The method of claim 1 , wherein the activated T cell clones are vaccine antigen-specific T cells.
8. The method of claim 1 , wherein the activated T cell clones are CD8 + effector T cells.
9. The method of claim 1 , wherein the vaccine is a vaccine for an infectious agent or a cancer vaccine.
10. The method of claim 1 , further comprising:
performing high-throughput sequencing of nucleic acid molecules comprising rearranged CDR3 regions of TCR loci obtained from a second biological sample of the subject at a second time point post vaccination; and
identifying newly recruited memory T cell clones corresponding to the vaccine-induced responsive clones that have been recruited to a memory T cell population post vaccination.
11. The method of claim 10 , wherein the identifying newly recruited memory T cell clones comprises sorting memory T cells by flow cytometry.
12. The method of claim 10 , wherein identifying newly recruited memory T cell clones comprises comparing a first set of memory T cell clones in the first biological sample to a second set of memory T cell clones in the second biological sample to identify one or more newly recruited memory T cell clones that have been recruited to the memory T cell population post vaccination.
13. The method of claim 12 , further comprising comparing the identified one or more newly recruited memory T cell clones with one or more vaccine-induced responsive clones from the set of activated T cells to find matches between the newly recruited memory T cell clones and the one or more vaccine-induced responsive clones.
14. The method of claim 13 , wherein the matched memory T cell clones are a significant number of the vaccine-induced responsive clones and are identified as biomarkers for vaccine-specific response.
15. The method of claim 13 , wherein the matched memory T cell clones are a significant proportion of total memory T cell population and are identified as biomarkers for vaccine-specific response.
16. The method of claim 10 , wherein the memory T cell clones are CD8 + CD45RO + CD62L lo effector memory T cells.
17. The method of claim 10 , wherein the memory T cell clones are CD8 + CD45RO + CD62L hi central memory T cells.
18. The method of claim 10 , wherein the second time point is at least 30 days post vaccination.
19. A method of measuring a T cell response to an infection in a subject, comprising:
performing high-throughput sequencing of nucleic acid molecules comprising rearranged CDR3 regions of TCR loci obtained from a first biological sample of the subject at a first time point post infection, wherein the infection is selected from the group consisting of viral infection, bacterial infection, and parasitic infection;
sorting activated T cells from a subset of the first biological sample using flow cytometry to generate a set of activated T cells;
performing high-throughput sequencing of nucleic acid molecules comprising rearranged CDR3 regions of TCR loci obtained from the set of activated T cells; and
identifying activated T cell clones in the set having CDR3 regions of significantly higher proportional abundance in the activated T cell population in comparison to the first biological sample, thereby identifying infection-induced responsive clones.
20. The method of claim 19 , further comprising:
performing high-throughput sequencing of nucleic acid molecules comprising rearranged CDR3 regions of TCR loci obtained from a second biological sample of the subject at a second time point post infection; and
identifying newly recruited memory T cell clones corresponding to the infection-induced responsive clones that are not present in the first biological sample and that have been recruited to a memory T cell population post infection.
21. The method of claim 20 , wherein identifying newly recruited memory T cell clones comprises comparing a first set of memory T cell clones in the first biological sample to a second set of memory T cell clones in the second biological sample to identify one or more newly recruited memory T cell clones that have been recruited to the memory T cell population post infection.
22. The method of claim 19 , wherein the viral infection is an acute viral infection.